Literature DB >> 31356413

Clinical Outcome of Autologous Cultivated Oral Mucosal Epithelial Transplantation in Ocular Surface Reconstruction.

Vidya Gopakumar1,2, Shweta Agarwal3, Bhaskar Srinivasan3, Subramanian Krishnakumar1, Uma Maheswari Krishnan2, Geetha Iyer3.   

Abstract

PURPOSE: To evaluate the outcomes of autologous cultivated oral mucosal epithelial transplantation (COMET) in ocular surface reconstructive procedures.
METHODS: Twenty-five eyes of 24 patients who underwent COMET for ocular surface reconstruction were studied retrospectively from April 2011 to March 2014. Oral mucosal biopsy of 2 mm was harvested from all patients and cultured on amniotic membrane for 14 days. COMET was performed as a means to achieve corneal epithelization (group 1) and for fornix reconstruction (group 2). The extent of epithelization achieved (group 1) and the depth of the fornix reconstructed (group 2) were the primary outcome measures.
RESULTS: Six eyes of 5 patients [2 chemical injury (CI), 3 Stevens-Johnson Syndrome (SJS)] underwent COMET for nonhealing of an epithelial defect within a month after insult or had a nonhealing defect since insult despite maximal medical/surgical therapy. Group 2 included 19 eyes of 19 patients (10 CI, 8 SJS, 1 ocular cicatricial pemphigoid) which underwent COMET for fornix reconstruction. Postsurgery, the cornea was fully epithelized in 66.67% of the eyes (n = 4) and partially epithelized in 33.33% of the eyes (n = 2). The overall improvement in surface epithelization was statistically significant (P = 0.046). Reconstruction of an anatomically deep fornix was achieved in 57% of the eyes (4 CI, 6 SJS and 1 ocular cicatricial pemphigoid). The fornix was partially formed in 26% of the eyes (4 CI and 1 SJS). The overall improvement in fornix reconstruction was considered statistically significant (P = 0.024). The follow-up ranged from 1 to 5 to 27 months with a mean follow-up of 18 months SD ±8.9.
CONCLUSIONS: COMET, by providing an alternate source of epithelium, aids in faster epithelization and thus can be considered as an option in management of severe grade CI or SJS in the acute stage as well as in fornix reconstructive procedures in chronic stage of ocular surface disorders.

Entities:  

Year:  2019        PMID: 31356413     DOI: 10.1097/ICO.0000000000002082

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  5 in total

Review 1.  [Conjunctival reconstruction-State of the art of regenerative treatment forms beyond the limbus].

Authors:  Kristina Spaniol; Maria Borrelli; Johannes Menzel-Severing; Gerd Geerling
Journal:  Ophthalmologie       Date:  2022-06-14

2.  Cytokeratin profile and keratinocyte gene expression in keratinized lid margins of patients with chronic Stevens-Johnson syndrome.

Authors:  Madhuri Amulya Koduri; Jilu Jaffet; Swapna S Shanbhag; Sayan Basu; Vivek Singh; Swati Singh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-04-23       Impact factor: 3.535

3.  Challenges in the management of bilateral eyelid closure in Stevens-Johnson Syndrome.

Authors:  Yulia Aziza; Kohei Harada; Mayumi Ueta; Hideki Fukuoka; Shigeru Kinoshita; Chie Sotozono
Journal:  Am J Ophthalmol Case Rep       Date:  2022-03-05

Review 4.  Recent Advances in Stem Cell Therapy for Limbal Stem Cell Deficiency: A Narrative Review.

Authors:  Ali E Ghareeb; Majlinda Lako; Francisco C Figueiredo
Journal:  Ophthalmol Ther       Date:  2020-09-24

Review 5.  Acute and Chronic Management of Ocular Disease in Stevens Johnson Syndrome/Toxic Epidermal Necrolysis in the USA.

Authors:  Derek Metcalfe; Omer Iqbal; James Chodosh; Charles S Bouchard; Hajirah N Saeed
Journal:  Front Med (Lausanne)       Date:  2021-07-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.